| 任丽君,张麦叶,高彬.阿托伐他汀对2型糖尿病患者单核细胞toll样受体4表达和炎症因子的影响[J].安徽医药,2018,22(8):1558-1561. |
| 阿托伐他汀对2型糖尿病患者单核细胞toll样受体4表达和炎症因子的影响 |
| Effect of atorvastatin on the expression of toll-like receptor-4 and inflammatory factors in monocytes of patients with type 2 diabetes mellitus |
| 投稿时间：2017-02-23 |
| DOI： |
| 中文关键词: 阿托伐他汀 2型糖尿病 临床疗效 炎症因子 |
| 英文关键词: Atorvastatin Type 2 diabetes mellitus Clinical curative effect Inflammatory factor |
| 基金项目:陕西省自然科学基础研究计划项目(2015JM8471) |
|
| 摘要点击次数: 1973 |
| 全文下载次数: 711 |
| 中文摘要: |
| 目的 观察2型糖尿病患者单核细胞toll样受体4表达和炎症因子的变化情况,以及阿托伐他汀对其表达的影响。方法 选取2013年1月至2015年1月期间收治的60例2型糖尿病患者作为观察组,并选取同期在我院进行健康体检的60例正常人作为对照组。采用流式细胞仪检测单核细胞toll样受体4表达；采用酶联免疫吸附(ELISA)分别对血清相关因子水平进行测定。将观察组中的患者分为A组(n=30)和B组(n=30),其中A组患者予以常规的降糖治疗,B组患者在常规治疗基础上予以阿托伐他汀药物进行治疗。分别对两组患者的单核细胞toll样受体4表达和炎症因子水平变化情况以及治疗前后的血糖水平进行客观的评定和比较,同时比较两组患者治疗后临床疗效和血糖指标。结果 较对照组而言,观察组的单个核细胞TRL4 mRNA[(4.35±0.66)比(1.95±0.30)]和蛋白表达[(3.79±0.52)比(1.80±0.20)]明显升高(P<0.05)；与治疗后相比,A组患者的单个核细胞TRL4 mRNA和蛋白表达以及血浆肿瘤坏死因子-α(TNF-α)等水平差异无统计学意义(P>0.05),而B组患者治疗后的单个核细胞TRL4 mRNA [(2.09±0.40)比(4.76±0.55)]和蛋白表达[(1.99±0.33)比(4.60±0.47)]以及血浆TNF-α等水平[(9.10±0.76)比(18.66±1.32)]较治疗前明显降低,且更低于A组患者(P<0.05)；两组治疗前后的空腹血糖、餐后2 h血糖和糖化血红蛋白情况差异有统计学意义(P<0.05),两组组间的比较也差异有统计学意义(P<0.05)。结论 阿托伐他汀可以降低血清炎症因子的水平,且可以下调2型糖尿病患者的单核细胞toll样受体4表达,其的抗炎和抑制TLR4效果显著,可以发挥治疗作用。 |
| 英文摘要: |
| Objective To observe the expression of toll-like receptor-4 and inflammatory factors in monocytes of patients with type 2 diabetes mellitus and the effect of atorvastatin on its expression.Methods Sixty patients with type 2 diabetes mellitus admitted from January 2013 to January 2015 were selected as the observation group, and 60 healthy subjects were selected as the control group. The expression of toll-like receptor-4 in monocytes was detected by flow cytometry. The level of serum-associated factor was measured by enzyme-linked immunosorbent assay (ELISA). Patients in the observation group were divided into group A (n=30) and group B (n=30). Patients in group Awere treated with conventional hypoglycemic therapy and patients in group Bwere treated with atorvastatin based on conventional therapy treatment. The expression of toll-like receptor-4 and the change of inflammatory factors in monocytes were evaluated and compared. The clinical curative effect was compared between the two groups.Results Compared with the control group, the expression of TRL4 mRNA [(4.35±0.66) vs. (1.95±0.30)] and protein [(3.79±0.52) vs. (1.80±0.20)] in the mononuclear cells of the observation group were significantly increased (P<0.05). However, the levels of TRL4 mRNA [(2.09±0.40) vs. (4.76±0.55)] and protein expression [(1.99±0.33) vs. (4.60±0.47)] and plasma TNF-α [(9.10±0.76) vs. (18.66±1.32)] in mononuclear cells after treatment in group Bwere significantly lower than those in group B (P<0.05), and the levels of TRL4 mRNA and TNF-α were significantly lower (P<0.05). The total effective rate of group Awas lower than that of group B (P<0.05). The fasting blood glucose, postprandial 2 h blood glucose and glycosylated hemoglobin were significantly different between the two groups (P<0.05), and there was significant difference between the two groups (P<0.05).Conclusion Atorvastatin can decrease the levels of inflammatory cytokines and down-regulate the expression of toll-like receptor 4 in monocytes of type 2 diabetes mellitus patients. The anti-inflammatory and anti-TLR4 effects of atorvastatin are significant and the clinical curative effect is improved. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
